Cargando…

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

BACKGROUND: In phase I studies, poziotinib has shown meaningful efficacy against various types of cancers. This phase 2 study aimed to investigate the efficacy and safety of poziotinib in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M‐HNSCC). METHODS: Overall, 49 patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Hyun, Heo, Seong Gu, Ahn, Beung‐Chul, Hong, Min Hee, Cho, Byoung Chul, Lim, Sun Min, Kim, Hye Ryun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Researcher
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525103/ https://www.ncbi.nlm.nih.gov/pubmed/34528763 http://dx.doi.org/10.1002/cam4.4231

Ejemplares similares

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

The Tumor Immune Microenvironment Architecture Correlates with Risk of Recurrence in Head and Neck Squamous Cell Carcinoma
por: Weed, Donald T., et al.
Publicado: (2023)

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
por: Lee, Jii Bum, et al.
Publicado: (2022)

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence
por: Subramanian, Sundaram, et al.
Publicado: (2018)

FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma
por: Liang, Huazhen, et al.
Publicado: (2021)

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
por: Ahn, Beung-Chul, et al.
Publicado: (2019)

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
por: Huang, Kie Kyon, et al.
Publicado: (2016)

FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis
por: Huang, Junjie, et al.
Publicado: (2021)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
por: Guigay, Joël, et al.
Publicado: (2021)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Oldenburg, Reid, et al.
Publicado: (2021)

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
por: Lim, Sun Min, et al.
Publicado: (2019)

Predicting treatment outcomes using (18)F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
por: Kim, Chang Gon, et al.
Publicado: (2022)

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)
por: Oswald, Laura B., et al.
Publicado: (2020)

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
por: Kim, Seok-Young, et al.
Publicado: (2019)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Treatment Outcomes of Patients with Head and Neck Squamous Cell Carcinoma of Unknown Primary
por: Park, Kyeong Suk, et al.
Publicado: (2021)

Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer
por: Tsao, Anne, et al.
Publicado: (2013)

Quantitative ultrasound radiomics in predicting recurrence for patients with node‐positive head‐neck squamous cell carcinoma treated with radical radiotherapy
por: Dasgupta, Archya, et al.
Publicado: (2020)

Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness
por: Lee, Heejin, et al.
Publicado: (2020)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
por: Cho, Byoung Chul, et al.
Publicado: (2020)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Hypoxia promotes the tolerogenic phenotype of plasmacytoid dendritic cells in head and neck squamous cell carcinoma
por: Fan, Cui, et al.
Publicado: (2021)

Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium
por: Leoncini, Emanuele, et al.
Publicado: (2018)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
por: Lorch, Jochen H
Publicado: (2009)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review
por: Swartz, Justin E, et al.
Publicado: (2015)

Mitochondrial DNA copy number is associated with risk of head and neck squamous cell carcinoma in Chinese population
por: Wang, Lihua, et al.
Publicado: (2018)

Adherence of head and neck squamous cell carcinoma patients to tumor board recommendations
por: Rangabashyam, Mahalakshmi S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n7qjaj0dqk1slja4ppt1hkdnjm